(Total Views: 530)
Posted On: 07/26/2023 12:45:18 AM
Post# of 153988
Quote:
The FDA then denied approval. Their rationale? The drug helped "only" 44% of the patients.
The clinical trial showed p = .047. Statistically significant but barely. With 234 patients in the study the FDA my have wanted a larger trial.
The drug Ampligen is a TLR3 receptor agonist which would boost anti-viral activity. With viruses being implicated in CFS/ME it likely does have some benefit. But would also work against itself in the CFS/ME indication by increasing inflammatory activity.
(4)
(0)
